Brief: Gilead Sciences To Acquire Arcellx To Maximize Long-Term Potential Of Anito-Cel
23/02/2026 11:15
Arcellx Inc ACLX.O: GILEAD SCIENCES TO ACQUIRE ARCELLX TO MAXIMIZE LONG-TERM POTENTIAL OF ANITO-CEL GILEAD - TO BUY ARCELLX FOR $115 PER SHARE IN CASH GILEAD - DEAL REPRESENTS IMPLIED EQUITY VALUE OF $7.8 BILLION GILEAD - DEAL EXPECTED TO BE ACCRETIVE TO EPS IN 2028 AND THEREAFTER Source text: ID:nBw9F864Ha Further company coverage: ACLX.O
Recent news on Arcellx
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 02:18 PM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Gilead Extends Tender Offer To Acquire Arcellx
U.S. RESEARCH ROUNDUP-Arcellx, Costar Group, Magnite